Related Experiment Video
Updated: Aug 28, 2026

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
Published on: October 12, 2017
Type IIa hyperlipoproteinaemia. An evaluation of four therapeutic regimens
Abstract:
The cholesterol-lowering effect of clofibrate (Ciba-SU13437) cholestyramine and the combination of clofibrate and cholestyramine is studied in 19 subjects with type lla hyperlipoproteinaemia, over a 20-week period. Each regimen is evaluated in terms of total cholesterol-lowering effect, cholesterol-lowering effect at 4, 8 and 16 weeks of therapy, and the incidence of side-effects. Cholestyramine is identified as the agent of choice in the management of this disorder and recommendations for its optimal utilisation are put forward.
Related Concept Videos
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Insulin: Dosing Regimen and Adverse Effects
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Dipeptidyl Peptidase 4 Inhibitors
Blood Studies for Cardiovascular System III: Serum Lipid Profile
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
Atherosclerosis III: Management
Nephrotic Syndrome II : Assessment and Medical Management

